JZJing Zhang

Jing Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Zhang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Guanghui Ma

    National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences , No.1 Beierjie Street, Zhongguancun, Haidian District, Beijing 100190, China

    2 shared publications
  • Lianyan Wang

    Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    2 shared publications
  • Yongjie Chi

    Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    2 shared publications
  • Zhan Zhou

    National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences , No.1 Beierjie Street, Zhongguancun, Haidian District, Beijing 100190, China

    2 shared publications
  • Zhiguo Su

    State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    2 shared publications
  • Jiaxin Bao

    Key Laboratory of Green Process and Engineering, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    1 shared publication

Latest Publications

  • Open Access

    Virus-like Particles for TEM Regulation and Antitumor Therapy

    by Zhu Yang, Yongjie Chi, Jiaxin Bao, Xin Zhao, Jing Zhang, Lianyan Wang

    Tumor development and metastasis are intimately associated with the tumor microenvironment (TME), and it is difficult for vector-restricted drugs to act on the TME for long-term cancer immunotherapy. Virus-like particles (VLPs) are nanocage structures self-assembled from nucleic acid free viral proteins. Most VLPs range from 20–200 nm in diameter and can naturally drain into lymph nodes to induce robust humoral immunity. As natural nucleic acid nanocarriers, their surfaces can also be genetically or chemically modified to achieve functions such as TME targeting. This review focuses on the design ideas of VLP as nanocarriers and the progress of their research in regulating TME.


  • Open Access

    Ion Interference Therapy of Tumors Based on Inorganic Nanoparticles

    by Yongjie Chi, Peng Sun, Yuan Gao, Jing Zhang, Lianyan Wang

    As an essential substance for cell life activities, ions play an important role in controlling cell osmotic pressure balance, intracellular acid–base balance, signal transmission, biocatalysis and so on. The imbalance of ion homeostasis in cells will seriously affect the activities of cells, cause irreversible damage to cells or induce cell death. Therefore, artificially interfering with the ion homeostasis in tumor cells has become a new means to inhibit the proliferation of tumor cells. This treatment is called ion interference therapy (IIT). Although some molecular carriers of ions have been developed for intracellular ion delivery, inorganic nanoparticles are widely used in ion interference therapy because of their higher ion delivery ability and higher biocompatibility compared with molecular carriers. This article reviewed the recent development of IIT based on inorganic nanoparticles and summarized the advantages and disadvantages of this treatment and the challenges of future development, hoping to provide a reference for future research.


  • Open Access

    SK-Unet: an Improved U-net Model with Selective Kernel for the Segmentation of Multi-sequence Cardiac MR

    by Xiyue Wang, Sen Yang, Mingxuan Tang, Yunpeng Wei, Ling He, Jing Zhang, Xiao Han

    In the clinical environment, myocardial infarction (MI) as one com-mon cardiovascular disease is mainly evaluated based on the late gadolinium enhancement (LGE) cardiac magnetic resonance images (CMRIs). The auto-matic segmentations of left ventricle (LV), right ventricle (RV), and left ven-tricular myocardium (LVM) in the LGE CMRIs are desired for the aided diag-nosis in clinic. To accomplish this segmentation task, this paper proposes a modified U-net architecture by combining multi-sequence CMRIs, including the cine, LGE, and T2-weighted CMRIs. The cine and T2-weighted CMRIs are used to assist the segmentation in the LGE CMRIs. In this segmentation net-work, the squeeze-and-excitation residual (SE-Res) and selective kernel (SK) modules are inserted in the down-sampling and up-sampling stages, respective-ly. The SK module makes the obtained feature maps more informative in both spatial and channel-wise space, and attains more precise segmentation result. The utilized dataset is from the MICCAI challenge (MS-CMRSeg 2019), which is acquired from 45 patients including three CMR sequences. The cine and T2-weighted CMRIs acquired from 35 patients and the LGE CMRIs acquired from 5 patients are labeled. Our method achieves the mean dice score of 0.922 (LV), 0.827 (LVM), and 0.874 (RV) in the LGE CMRIs.

  • Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab′ Synthesis

    by Zhan Zhou, Jing Zhang, Yan Zhang, Guanghui Ma, Zhiguo Su

    Conventional preparation strategies for antibody–drug conjugates (ADCs) result in heterogeneous products with various molecular sizes and species. In this study, we developed a homogeneous preparation strategy by site-specific conjugation of the anticancer drug with an antibody fragment. The model drug doxorubicin (DOX) was coupled to the Fab′ fragment of anti-CD20 IgG at its permissive sites through a heterotelechelic PEG linker, generating an antibody fragment–drug conjugate (AFDC). Anti-CD20 IgG was digested and reduced specifically with β-mercaptoethylamine to generate the Fab′ fragment with two free mercapto groups in its hinge region. Meanwhile, DOX was conjugated with α-succinimidylsuccinate ω-maleimide polyethylene glycol (NHS-PEG-MAL) to form MAL-PEG-DOX, which was subsequently linked to the free mercapto containing Fab′ fragment to form a Fab′-PEG-DOX conjugate. The dual site-specific bioconjugation was achieved through the combination of highly selective reduction of IgG and introduction of heterotelechelic PEG linker. The resulting AFDC provides an utterly homogeneous product, with a definite ratio of one fragment to two drugs. Laser confocal microscopy and cell ELISA revealed that the AFDC could accumulate in the antigen-positive Daudi tumor cell. In addition, the Fab′-PEG-DOX retained appreciable targeting ability and improved antitumor activity, demonstrating an excellent therapeutic effect on the lymphoma mice model for better cure rate and significantly reduced side effects.


  • Comparison of Site-Specific PEGylations of the N-Terminus of Interferon Beta-1b: Selectivity, Efficiency, and in Vivo/Vitro Activity

    by Zhan Zhou, Jing Zhang, Lijing Sun, Guanghui Ma, Zhiguo Su

    PEGylation, including nonspecific and site-directed approaches, is a well-established and validated strategy to increase the stability, in vivo plasma retention time, and efficacy of protein pharmaceutics together with a reduction in immunogenicity and hydrophobicity. Site-directed conjugation by PEG-aldehyde is the most widely used method for N-terminal modification; however, the generation of multimodified products is inevitable because of lysine chemistry, which always leads to difficulties in purification and quantification. In this study, we developed a specific PEGylation strategy through the periodation of the N-terminus of interferon beta-1b (IFN-β-1b) followed by the coupling of PEG-hydrazide. The prolonged elimination half-life and significantly diminished immunogenicity of the PEG-hydrazide-modified protein indicated the development of an effective process for improving the pharmacology and immunogenicity of IFN-β-1b. We further conducted comparisons on the selectivity, velocity, yield, and pharmacokinetics of the two methods. The results demonstrated that the hydrazide-based conjugation was a highly specific coupling reaction that only produced homogeneous N-terminal mono-PEGylated conjugate but also generated heterogeneous multimodified products in the aldehyde-based process. In addition, a better PEGylation yield was found for the hydrazide conjugation compared with that of the aldehyde strategy. These investigations supply a practical approach for the site-specific modification of proteins with an N-terminal serine or threonine to achieve improved homogeneity of the conjugates as well as enhanced pharmacological properties.